fosdagrocorat   Click here for help

GtoPdb Ligand ID: 9649

Synonyms: PF-04171327
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Fosdagrocorat (PF-04171327) is a glucocorticoid (GC) receptor partial agonist with anti-inflammatory potential. It is an example of a new class of GC substances termed dissociated agonists of the GC receptors (DAGR), that are being developed to improve the risk-benefit profile of GC drugs. DAGRs are designed to favour interaction of the GC receptor with protein partners rather than DNA, such that the transrepressive actions are enhanced over the transactivation effects. The hypothesis is that dissociating transrepression from transactivation will cause less undesirable effects on bone and glucose metabolism compared to current GC agonists such as prednisone (reviewed in [1]). Fosdagrocorat is example 2 in Pfizer's patent US8901310 [3]. It is a phosphate ester prodrug of dagrocorat (example 1 in US8901310).
Synthesis and structure-activity relationship (SAR) of another series of DAGRs (by Boehringer Ingelheim Pharmaceuticals) are reported in [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 118.56
Molecular weight 574.18
XLogP 5.29
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES O=C(c1ccc2c(c1)CCC1C2(CCC(C1)(OP(=O)(O)O)C(F)(F)F)Cc1ccccc1)Nc1cccnc1C
Isomeric SMILES O=C(c1ccc2c(c1)CC[C@H]1[C@]2(CC[C@](C1)(OP(=O)(O)O)C(F)(F)F)Cc1ccccc1)Nc1cccnc1C
InChI InChI=1S/C29H30F3N2O5P/c1-19-25(8-5-15-33-19)34-26(35)22-10-12-24-21(16-22)9-11-23-18-28(29(30,31)32,39-40(36,37)38)14-13-27(23,24)17-20-6-3-2-4-7-20/h2-8,10,12,15-16,23H,9,11,13-14,17-18H2,1H3,(H,34,35)(H2,36,37,38)/t23-,27+,28-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Results of a Phase 2 clinical trial evaluating fosdagrocorat in patients with rheumatoid arthritis (RA) have been published [4], which report positive outcomes with regards to efficacy in improving RA signs and symptoms, with manageable adverse events. The efficacy of fosdagrocorat (10 and 15 mg/day) was equivalent to 10 mg/day prednisone, whereas its impact on biomarkers for bone formation and resorption, and plasma glucose were comparable to a lower prednisone dose of 5 mg/day.